Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Q3 Losses Up as Expenses Rise

Premium

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals last week reported its third-quarter financial results, posting higher losses amid increased spending on its drug-development programs.

Dicerna's net loss for the period rose to $11.2 million from $4.5 million the year before.

Meanwhile, research and development costs climbed to $7.5 million from $2.4 million, reflecting the initiation of clinical testing of its Phase I cancer drug DCR-MYC and preparations to advance the preclinical primary hyperoxaluria 1 treatment DCR-PH1 into human trials.

General and administrative expenses rose to $3.7 million from $1.3 million, in part due to the costs associated with operating as a public company following Dicerna's initial public offering earlier this year.

At the end of the quarter, Dicerna had cash, cash equivalents, and held-to-maturity investments totaling $111.9 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.